Get the Stockscreener App
2.72
6.21%
-0.18
After Hours:
2.73
0.010
+0.37%
Bioaffinity Technologies Inc stock is traded at $2.72, with a volume of 603.97K.
It is down -6.21% in the last 24 hours and down -64.51% over the past month.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.
See More
Previous Close:
$2.90
Open:
$2.86
24h Volume:
603.97K
Relative Volume:
0.26
Market Cap:
$8.42M
Revenue:
$9.37M
Net Income/Loss:
$-8.45M
P/E Ratio:
-3.358
EPS:
-0.81
Net Cash Flow:
$-7.27M
1W Performance:
+4.21%
1M Performance:
-64.51%
6M Performance:
-83.81%
1Y Performance:
-95.30%
1-Day Range:
$2.6501
$3.05
1-Week Range:
$2.3401
$3.65
52-Week Range:
$2.3401
$67.12
Bioaffinity Technologies Inc Stock (BIAF) Company Profile
Name
Bioaffinity Technologies Inc
Sector
Industry
Phone
210-698-5334
Address
3300 NACOGDOCHES ROAD, SAN ANTONIO
Compare BIAF with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BIAF
Bioaffinity Technologies Inc
|
2.72 | 8.42M | 9.37M | -8.45M | -7.27M | -0.81 |
|
TMO
Thermo Fisher Scientific Inc
|
524.80 | 201.90B | 43.21B | 6.58B | 6.17B | 17.28 |
|
DHR
Danaher Corp
|
202.46 | 146.42B | 24.01B | 3.41B | 4.86B | 4.7082 |
|
IDXX
Idexx Laboratories Inc
|
616.15 | 50.30B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
136.62 | 39.72B | 6.79B | 1.22B | 1.09B | 4.2644 |
|
IQV
Iqvia Holdings Inc
|
198.17 | 34.51B | 15.70B | 1.24B | 2.01B | 6.9036 |
Bioaffinity Technologies Inc Stock (BIAF) Latest News
Key resistance and support levels for bioAffinity Technologies Inc. Equity WarrantTake Profit & Fast Entry High Yield Tips - newser.com
Biotech Stocks To Follow TodayOctober 8th - MarketBeat
Is bioAffinity Technologies Inc. building a consolidation base2025 Fundamental Recap & Free Community Consensus Stock Picks - newser.com
How to track smart money flows in bioAffinity Technologies Inc. Equity WarrantVolume Spike & Reliable Entry Point Alerts - newser.com
Visual trend scoring systems applied to bioAffinity Technologies Inc. Equity WarrantJuly 2025 Volume & Trade Opportunity Analysis - newser.com
Is bioAffinity Technologies Inc. Equity Warrant stock attractive for retirement portfoliosJuly 2025 Technicals & Safe Capital Growth Plans - newser.com
Developing predictive dashboards with bioAffinity Technologies Inc. data2025 Analyst Calls & Weekly High Momentum Picks - newser.com
Will bioAffinity Technologies Inc. stock maintain momentum in 2025July 2025 Short Interest & AI Optimized Trading Strategy Guides - newser.com
bioAffinity Technologies Announces $1.8M Direct Offering - MSN
bioAffinity Technologies, Inc. Announces Closing of $1.8 Million Registered Direct Financing of Comm - PharmiWeb.com
$1.8M Registered Direct Offering: bioAffinity Closes 720K Shares to Fund CyPath Lung Sales - Stock Titan
bioAffinity Technologies closes $1.8 million registered direct offering - Investing.com India
BioAffinity Technologies Closes $1.8 Million Registered Direct Offering - MarketScreener
bioAffinity Technologies, Inc. Announces Closing of $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules - Business Wire
What analysts say about bioAffinity Technologies Inc stockLong-Term Growth Stocks & Affordable Portfolio Growth - earlytimes.in
Can trapped investors hope for a rebound in bioAffinity Technologies Inc.2025 Buyback Activity & Reliable Entry Point Alerts - newser.com
Exit strategy if you’re trapped in bioAffinity Technologies Inc.Gap Up & Low Risk Entry Point Guides - newser.com
Does bioAffinity Technologies Inc. Equity Warrant fit your quant trading modelWeekly Trend Recap & Stock Portfolio Risk Control - newser.com
How to build a dashboard for bioAffinity Technologies Inc. stockTrade Risk Report & Long-Term Safe Return Strategies - newser.com
Signal strength of bioAffinity Technologies Inc. stock in tech scannersWeekly Trend Summary & AI Enhanced Market Trend Forecasts - newser.com
Why bioAffinity Technologies Inc. stock appeals to analystsQuarterly Profit Report & Daily Growth Stock Tips - newser.com
How to read the order book for bioAffinity Technologies Inc.July 2025 Levels & Low Drawdown Momentum Ideas - newser.com
BioAffinity Technologies Launches $1.8 Million Registered Direct Offering - MarketScreener
bioAffinity Technologies raises $1.8 million in registered direct offering By Investing.com - Investing.com Nigeria
WallachBeth Capital announces bioaffinity technologies - MarketScreener
bioAffinity Technologies raises $1.8 million in registered direct offering - Investing.com India
WallachBeth Capital Announces bioAffinity Technologies Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules - cnhinews.com
bioAffinity Technologies raises $1.8 million in direct offering - Investing.com
BioAffinity Technologies announces $1.8M registered direct offering - TipRanks
bioAffinity Technologies, Inc. Announces Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules - The Joplin Globe
$1.8M registered direct raise — bioAffinity to sell 720K shares to fund CyPath Lung sales - Stock Titan
BioAffinity Technologies Stock Surges: What’s Next? - StocksToTrade
What's Driving bioAffinity Technologies' Big Pre-Market Surge? - Benzinga
bioAffinity Technologies Reports Record Growth in CyPath® Lung Test Volume for Third Quarter 2025 - BioSpace
bioAffinity Technologies reports 95% quarterly sales growth for lung test By Investing.com - Investing.com Canada
bioAffinity Technologies Reports 95% Sales Surge in Q3 2025 - TipRanks
BioAffinity's lung cancer test sales soar 95% as veterans' hospitals drive adoption - The Business Journals
BioAffinity Technologies reports record growth for CyPath Lung diagnostic test - TipRanks
bioAffinity Technologies reports 95% quarterly sales growth for lung test - Investing.com India
bioAffinity Technologies Inc Stock Analysis and ForecastSupport and Resistance Levels & Outstanding Portfolio Tips - earlytimes.in
Published on: 2025-10-06 06:37:07 - newser.com
Predicting bioAffinity Technologies Inc. Equity Warrant trend using moving averagesJuly 2025 Review & Weekly High Potential Stock Alerts - newser.com
Applying chart zones and confluence areas to bioAffinity Technologies Inc.Short Setup & Capital Efficient Trade Techniques - newser.com
Can swing trading help recover from bioAffinity Technologies Inc. Equity Warrant losses2025 Volatility Report & Safe Capital Growth Stock Tips - newser.com
News impact scoring models applied to bioAffinity Technologies Inc.Market Activity Summary & Technical Pattern Based Buy Signals - newser.com
Using data tools to time your bioAffinity Technologies Inc. exitTrade Volume Report & Weekly Stock Breakout Alerts - newser.com
Analyzing bioAffinity Technologies Inc. with multi timeframe chartsTrade Exit Summary & Weekly Stock Breakout Alerts - newser.com
Is bioAffinity Technologies Inc. stock a buy on dipsTrade Risk Report & AI Based Buy and Sell Signals - newser.com
bioAffinity Technologies Stock Price, Quotes and Forecasts | NASDAQ:BIAF - Benzinga
Will bioAffinity Technologies Inc. Equity Warrant stock remain a Wall Street favoriteEntry Point & High Accuracy Swing Trade Signals - newser.com
Why bioAffinity Technologies Inc. stock is in analyst buy zoneEntry Point & Low Risk Entry Point Tips - newser.com
Bioaffinity Technologies Inc Stock (BIAF) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.17%
2.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):